Sitagliptin (known as Januvia) has been approved by the European Commission as an add-on to insulin (with or without metformin) for people with Type 2 diabetes who cannot control their condition effectively with a combination of diet, physical activity and insulin. Sitagliptin is a once-daily DPP-4 inhibitor that works by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
Incretins help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed.
Further option for people with Type 2 diabetes
“We welcome any advances that help improve quality of life for people with diabetes," said Pav Kalsi, Care Advisor at Diabetes UK.
"When it is not possible for people with Type 2 diabetes to achieve good blood glucose control through lifestyle and current medication, Diabetes UK recognises that a wide choice of treatment options, including Januvia (sitagliptin) in combination with insulin, can help.
“People with diabetes should have as wide a choice as possible of effective treatments for their condition. Good blood glucose control is essential for people with diabetes to improve wellbeing and protect against long-term damage to the eyes, kidneys, nerves, heart and major arteries.”